OptIMMize-2: A Phase 3 Multicenter, Single-arm, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Risankizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Completed Participation in Study M19-977 (OptIMMize-1)

Date Added
November 17th, 2022
PRO Number
Pro00122906
Researcher
Lara Wine Lee

List of Studies


Keywords
Adolescents, Skin
Summary

This is a Phase 3 multicenter, single-arm, open-label extension (OLE) study designed to investigate the long-term safety, tolerability, and efficacy of risankizumab 150 mg or 55 mg by weight every 12 weeks (Q12W) in the treatment of moderate to severe plaque Ps in eligible subjects who have completed all assessments in Study M19-977 and elect to participate in Study M19-973. The study is comprised of a 216-week treatment period and a follow-up phone call for safety approximately 140 days (20 weeks) after the last dose of study drug.

Institution
MUSC
Recruitment Contact
Alyson Winter
843-876-3209
wintera@musc.edu

The Cultural Adaptation of an Alcohol and Other Drug Use Treatment for Black Justice Involved Youth.

Date Added
September 14th, 2022
PRO Number
Pro00122199
Researcher
Brittany Bryant

List of Studies